JP6427366B2 - Chemical volatilization device - Google Patents

Description

  The present invention relates to a chemical volatilization apparatus suitable for the user to wear and use outdoors, etc., in order to control and repel flying pests such as mosquitoes and flies.

DESCRIPTION OF RELATED ART Conventionally, the insect repellent which exterminates and repels a pest by volatilizing the normal temperature volatile insect repellent in air is known.
For example, Patent Documents 1 and 2 disclose a portable pest control device that rotates an internal rotating body by moving a body or a portable item, and volatilizes a drug from a drug holding body to control a pest.
Further, Patent Document 3 discloses an apparatus for volatilizing a drug by causing a resin molded body, which is a drug holding body, to perform a pendulum motion.

Patent No. 5051904 gazette Patent No. 4485544 JP 2014-83023 A

  However, the portable control devices disclosed in Patent Literatures 1 and 2 do not necessarily provide the rotation necessary for volatilizing the drug from the drug holder if the movement of the body or the portable item is not sufficient, and the pest control is not always necessary. There was a problem that the function could not be fully exhibited. In addition, there are many parts needed to rotate the drug, assembly effort is required, and failures may occur. In addition, the drug volatilization device using pendulum motion disclosed in Patent Document 3 needs to increase the size of the device for moving as the weight of the resin molded body which is the drug holding member increases, so that the portable type Was not suitable as a control device for

  The present invention has been made in view of the above-mentioned problems, and the purpose thereof is to efficiently volatilize the active ingredient of the drug for a long period of time without providing a driving means such as a battery or a motor, and to use the type of drug. Accordingly, it is possible to exert an effect such as controlling pests, and to manufacture it simply and compactly.

The present invention has been found out that the following constitution has excellent effects to achieve the above object.
[1] A drug volatilization apparatus storing a drug volatilization body having a carrier carrying a normal temperature volatile drug on a carrier inside a storage container having an opening, wherein the opening is at least on the side surface and the front surface of the storage container And the drug volatilization body is swingably suspended inside the storage container, and the swing angle of the drug volatilization body is 0.05π (9 °) to 0.5π (90 °). And, when the drug volatilization body oscillates, volatilization of the volatilization drug contained in the drug volatilization body is caused, or the volatilization amount thereof is increased, and the gaseous drug which is the volatilization drug which volatilized is The chemical vaporization apparatus which moves to the space part in the said storage container from the space | gap part of a chemical | medical agent volatilization body, and sends it out from the said opening part.

[2] The ratio (C) of the area of the opening of the side part to the area of the whole side of the storage container, and the ratio of the area of the opening of the front part to the area of the whole front of the storage (D) The chemical volatilization apparatus according to [1], wherein the ratio C / D to (C) is 0.3 to 3.0.
[3] The area ratio (C) of the opening of the side surface portion is 10 to 50%, and the area ratio (D) of the opening of the front surface portion is 10 to 50%. The agent volatilization apparatus as described in [2] whose / D is 0.3-3.0.
[4] The drug volatilization device according to any one of [1] to [3], wherein the drug volatilization body is suspended at one point.

[5] The drug volatilization device according to any one of [1] to [4], wherein the drug uses at least one drug selected from transfluthrin, metfluthrin, enpentrin, and profluthrin.
[6] The area of the opening provided in the back of the storage container is 10% or less of the total area of the back of the storage container according to any one of [1] to [5] Chemical stripping equipment.
[7] The volume ratio (A / B) of the bulk volume (A) of the drug volatilization body to the volume (B) inside the storage container is 0.01 to 0.6 [1] to [6] ] The chemical | medical-agent volatilization apparatus of any one of].

[8] The chemical volatilization apparatus according to any one of [1] to [7], wherein the carrier is a tabular or steric structure composed of a fiber component or a resin component.
[9] The drug volatilization apparatus according to [8], wherein the carrier has a mesh structure having voids.
[10] The drug vaporization apparatus according to any one of [1] to [9] is a portable drug vaporization apparatus.

  According to the present invention, it is possible to efficiently volatilize the active ingredient of the drug for a long period of 60 days or more and control pests according to the type of drug without providing a driving means such as a battery or a motor. And can be compact and inexpensive to manufacture.

(A) a perspective view showing an example of a three-dimensional structure, (b) a front view of (a), (c) a cross-sectional view of (c) (b) (A)-(c) The figure which shows the cross-sectional shape of the resin rod-shaped body or the resin filament concerning this invention The partially cutaway perspective view which shows the example of the chemical volatilization apparatus concerning this invention (A) a-a sectional view of FIG. 3, (b) a sectional view showing a state where the drug volatilization body of (a) is swung, (c) swinging the drug volatilization body of FIG. 3 in another direction C-c sectional view showing the broken state (A) to (d) a cross-sectional view of an example of a storage container used in the present invention viewed from the top The schematic diagram which showed the usage example of the chemical volatilization apparatus concerning this invention

  Hereafter, the chemical volatilization apparatus which is this invention is demonstrated in detail. In addition, although the case where what performs pest control as a chemical | medical agent is employ | adopted is demonstrated in the following embodiment, it can apply not only to this but various chemical | medical agents in particular.

  The present invention relates to a drug volatilization apparatus in which a drug volatilization body in which a carrier is made to carry a normal-temperature volatilizable drug is stored inside a storage container.

[Temperature volatile chemicals]
The normal temperature volatile drug (hereinafter referred to as "normal temperature volatile drug") is a drug that exhibits volatilization at normal temperature, and examples thereof include pyrethroid-type insect repellent components at normal temperature.
As this normal temperature volatilizable drug, a drug which has the property of volatilizing in air at normal temperature, and a drug having a vapor pressure of about 0.001 Pa or more and 0.1 Pa or less at 25 ° C. is preferable because it can exhibit appropriate volatilization.

  Specific examples of the cold volatilizable pyrethroid type insect repellent component include at least one of metfluthrin, profluthrin, transfluthrin, and enpentrin from the viewpoint of volatilization performance and safety. In addition, although various optical isomers or geometric isomers exist about these insect-repellent components, even if it is an individual and a mixture, any isomers can also be used.

  In addition to the normal temperature volatilizable drug, a flying pest repellent flavor composition or other additives may be added to the drug volatilization body.

[Flight pest repellent flavor composition]
The flying pest repellent flavor composition is a composition containing a flying pest repellent flavor and a repellent effect sustaining component, and is added especially for the purpose of imparting a fragrance and reinforcing an insect repellent effect at an early stage of use.
As the flying pest repellent flavoring agent, at least one flavoring component selected from an acetic acid ester compound represented by the following general formula (I) and / or an allyl ester compound represented by the general formula (II) Examples of the component include (a) and one or two or more flavor components (b) selected from monoterpene alcohols or aromatic alcohols having 10 carbon atoms.
CH ₃ -COO-R ₁ (I)
(Wherein, R ₁ represents an alcohol residue having 6 to 12 carbon atoms.)
R ₂ -CH ₂ -COO-CH ₂ -CH = CH ₂ (II)
(Wherein R ₂ represents an alkyl group having 4 to 7 carbon atoms, an alkoxy group, a cycloalkyl group, a cycloalkoxy group, or a phenoxy group.)

  Specific examples of the acetic acid ester compound represented by the general formula (I) include p-tert-butylcyclohexyl acetate, o-tert-butylcyclohexyl acetate, p-tert-pentylcyclohexyl acetate, tricyclodecenyl acetate, Benzyl acetate, phenylethyl acetate, styrylyl acetate, anicyl acetate, cinnamyl acetate, terpinyl acetate, dihydroterpinyl acetate, linalyl acetate, ethyl linalyl acetate, citronellyl acetate, geranyl acetate, neryl acetate, bornyl acetate And isobornyl acetate and the like.

  Further, specific examples of the allyl ester compound represented by the general formula (II) include allyl hexanoate, allyl heptanoate, allyl octanoate, allyl isobutyl oxyacetate, allyl n-amyl oxy acetate, allyl cyclohexyl acetate And allyl cyclohexyl propionate, allyl cyclohexyl oxyacetate, allyl phenoxy acetate and the like.

  Further, specific examples of the component (b) include terpineol, geraniol, dihydromyrcenol, borneol, menthol, citronellol, nerol, linalool, ethyl linalool, thymol, eugenol, and p-menthane-3,8-diol and the like. can give.

  The blending ratio of (a) to (b) is preferably 0.1 to 2.0 times. Within this range, it is recognized that a high repellent effect can be exerted against flying pests.

  In addition, as the flying pest repellent flavor, flavor components other than the above, for example, monoterpene hydrocarbons such as limonene, menthol, carvone, monoterpene ketones such as camphor, camphor, damascone, citral, citronellal, neral, perilla Monoterpene aldehydes such as aldehydes, ester compounds such as cinnamyl formate, geranyl formate, phenylethyl alcohol, diphenyl oxide, indralome, or various essential oils containing the above-mentioned perfume components, eg, jasmine oil, neroli oil, Peppermint oil, bergamot oil, orange oil, geranium oil, petit gren oil, lemon oil, citronella oil, lemongrass oil, cinnamon oil, eucalyptus oil, lemon eucalyptus oil, thyme oil, etc. may be added as appropriate.

  It is preferable to use 1 type, or 2 or more types of glycol and / or glycol ether with a vapor pressure of 0.2 to 20 Pa at 20 ° C. as the repelling effect maintaining component. Conventionally, glycols and / or glycol ethers are listed as solvents in the same line as ethanol, isopropanol, kerosene, etc., and the effect on flying pests is not mentioned at all. Or, glycol ether not only acts as a solvent, but also exerts a sustained action of repellent effect specifically to the flying pest repellent perfume, and can maintain the initial flavor if the aromatic flying pest repellent perfume is used Found out.

  Specific examples of the repellent effect-retaining component (including vapor pressure at 20 ° C.) include propylene glycol (10.7 Pa), dipropylene glycol (1.3 Pa), tripropylene glycol (0.67 Pa), and diethylene glycol (diethylene glycol (0.67 Pa)). 3 Pa), triethylene glycol (1 Pa), 1,3-butylene glycol, hexylene glycol (6.7 Pa), benzyl glycol (2.7 Pa), diethylene glycol monobutyl ether (3 Pa), dipropylene glycol monobutyl ether, and tripropylene Glycol monomethyl ether is mentioned, among which dipropylene glycol is preferred.

  The compounding ratio of the repellent effect persistent component to the flying pest repellent perfume is preferably 0.2 to 10 times. Within this range, the repelling effect can be sufficiently sustained for the flying pest repellent fragrance.

  By the way, when mix | blending the said flying pest repellent fragrance composition, the compounding ratio with respect to the said normal temperature volatilization pyrethroid type | mold insect repellent component is about 0.2 to 2 times amount suitable. If the blending amount of the perfume composition is too small, the purpose of imparting the aroma can not be achieved, while if too much, the aroma is too strong and volatilization of the insect repellent component may be affected, which is not preferable.

  In the case of using the flying pest repellent flavor composition, when preparing the insect repellent component-containing resin pellet, the flying pest repellent flavor composition may be contained, but the insect repellent component-containing resin pellet and the flying pest repellent flavor It is preferable to knead both pellets after preparing each of the component-containing pellets. This is because the heating temperature at the time of production of the flying pest repellent flavor component-containing pellet is 90 ° C. to 130 ° C., which is lower than 110 ° C. to 140 ° C. in the case of the insect-repellent component-containing resin pellet. It is because it is advantageous in reducing loss to a highly volatile perfume composition.

[Other additives]
The drug volatilization body of the present invention can contain the flying pest repellent fragrance composition, in particular, for the purpose of imparting a fragrance and reinforcing an insect repellent effect at an early stage of use, as described above, but additionally Persistent perfume ingredients capable of sustaining fragrance over a period of time, for example, galaxolide, musk ketone, ethylene brushate, methyl atarate etc. may be blended as needed.

  Furthermore, synergists, repellents, antibacterial agents, fungicides, other functional components, etc. can also be used at the same time. For example, as said synergist, isobornyl thiocyanoacetate (trade name: IBTA) N-octylbicycloheptenecarboximide (trade name: cinepyline 222), N- (2-ethylhexyl) -1-isopropyl-4-methylbicyclo [2,2,2] oct-5-ene-2,3- Dicarboximide (trade name: Sinepyrin 500) and the like can be mentioned.

  As the repellent agent, N, N-diethyl-m-toluamide (trade name: Dieto), dimethyl phthalate, dibutyl phthalate, 2-ethyl-1,3-hexanediol, 1,4,4a, 5a, 6,6, 9,9a, 9b-octahydrodibenzofuran-4a-carbaldehyde etc. are mentioned.

  Examples of the antibacterial agent include hinokitiol, tetrahydrolinalool, eugenol, citronellal, allyl isothiocyanate and the like.

  Examples of the fungicide include isopropylmethylphenol and orthophenylphenol.

  Examples of the other functional components include green leaf alcohol called “green scent” and stress reducing components containing green leaf aldehyde.

  Furthermore, a coloring agent (coloring pigment), an antistatic agent, etc. may be appropriately blended, and if the color is added or the time indicator can be attached so that the end point of use can be visually recognized, the commercial value is further enhanced. Can.

  Although all of the normal temperature volatile chemicals used in the present invention have sufficient stability, it is possible to add a stabilizer such as an antioxidant in order to further enhance the stability, for example, 2, 2'-Methylenebis (4-ethyl-6-t-butylphenol), 4,4'-methylenebis (2-methyl-6-t-butylphenol), BHT, BHA, 3,5-di-t-butyl-4-hydroxy Anisole, mercaptobenzimidazole and the like can be used.

  In addition, by using an ultraviolet absorber such as paraaminobenzoic acid, cinnamic acid, salicylic acid, benzophenone and benzotriazole as an ultraviolet absorption inhibitor, light resistance during storage and use can be further improved.

[Carrier]
Next, the carrier constituting the drug volatilization body is a flat plate-like or three-dimensional structure composed of a fiber component or a resin component.

The resin component refers to a component composed of a resin composition described later.
Further, the fiber component means a fiber-like one, and long fibers (filaments) themselves, long fibers and short fibers (staples) may be twisted to form fibers. In the present invention, it is preferable to use long fibers (filaments), and it is preferable to use resin-made long fibers (resin filaments) obtained using a resin composition described later as the material, in particular, because the durability is high.

  The flat or three-dimensional structure refers to a structure having a mesh-like structure having a flat or three-dimensional void. Examples of this planar structure include a net, a lattice structure, and the like.

[Resin composition]
The resin composition used for the resin component and the fiber component is obtained by kneading the component resin with a fine powder component and another resin as required. Once the resin composition has been formed into pellets, it is effective to knead and form the above-mentioned normal temperature volatile chemicals or to carry out direct molding to impregnate the normal temperature volatile chemicals from the viewpoint of efficiency. preferable.

  As this constituent resin, it differs somewhat depending on whether a cold volatile chemical is kneaded or impregnated. That is, in the case of the former, the component resin is not particularly limited as long as the insect repellent component mixed in the inside of the carrier can be gradually bled and volatilized to the surface, for example, polyethylene resin or polypropylene Olefin-unsaturated carboxylic acid ester copolymer obtained by copolymerizing polyolefin resin such as acrylic resin or olefin such as ethylene and propylene and monomer such as unsaturated carboxylic acid ester (hereinafter referred to simply as “polyolefin” May be referred to as "copolymer") and the like. The unsaturated carboxylic acid ester is effective for controlling the volatilization of the insect-repellent component from the surface of the resin when it is a polyolefin copolymer, and, for example, methyl acrylate, ethyl acrylate, Methyl methacrylate, ethyl methacrylate, vinyl acetate and the like can be mentioned.

  In addition, since the compounding ratio of these unsaturated carboxylic acid ester monomers with respect to the said olefin generally tends to delay the bleeding speed of an insect-repellent component, so that the unsaturated carboxylic acid ester monomer compounding ratio becomes high, it is used It may be suitably adjusted in the range of 1 to 30% by mass with respect to the olefin, depending on the type and content of the insect repellent component to be used, or the purpose of use.

  Further, as the resin composition, a polymer obtained by mixing a polyolefin-based copolymer containing a large amount of unsaturated carboxylic acid ester monomer and a polyolefin-based resin such as a homopolymer of olefin in advance by adjusting its content ratio Blends can be used, and, if necessary, other high molecular compounds such as styrenic thermoplastic elastomers can be contained.

In the present invention, an ethylene-vinyl acetate copolymer using vinyl acetate as the unsaturated carboxylic acid ester is preferable in terms of performance, usability, etc., and the equivalent ratio of ethylene unit to vinyl acetate unit in it is 90: 10 to 70:30. If the amount of the vinyl acetate unit is too small, the physical properties are almost the same as polyethylene, and the bleeding adjustment effect required in the present invention can hardly be expected. On the other hand, when there are too many vinyl acetate units, it will become difficult to shape | mold into resin pellet form.
The melt mass flow rate (MFR) of the ethylene-vinyl acetate copolymer is preferably 5 g / 10 min or more and 50 g / 10 min or less. If the MFR is too small, the effect as a bleed regulator can not be expected, and if the MFR is too large, the influence on the physical properties of the resin pellet may not be negligible.

  As a preferable embodiment in the present invention, a resin composition kneaded with 10% by weight or more and 90% by weight or less of an ethylene-vinyl acetate copolymer and / or an ethylene-methyl methacrylate copolymer can be mentioned. This makes it possible to adjust the bleed in an appropriate range when the above-mentioned normal temperature volatile drug is kneaded to form a drug volatile body.

On the other hand, in a chemical volatilization body of the type in which a normal temperature volatilization chemical is impregnated, a resin which is non-adsorbable to an insect repellent component such as polyethylene terephthalate (PET) or polybutylene terephthalate (PBT) is mainly used as a constituent resin. Is common.
In this case, the insect repellent component is supported on the surface of the carrier having a three-dimensional mesh and subjected to volatilization, and such a resin composition is blended with a resin such as the above-mentioned polyolefin resin, styrene thermoplastic elastomer, or rayon. Then, the constituent resin can be reformed to adjust the volatilization of the insect repellent component.

[Drug eliminator]
The drug volatilization body is constituted by containing the normal temperature volatile drug in the carrier. As a method of containing the normal temperature volatile drug, a method of preparing the drug holding resin composition by kneading the normal temperature volatile drug with the above-mentioned resin composition, and then molding it can be mentioned. Moreover, when using the said fiber component, first, a long fiber (resin filament) and a short fiber are manufactured from the said resin composition, and then resin filaments or these are twisted together and what was made into fibrous form is twisted together. Examples include a method of forming a three-dimensional mesh and impregnating the above-mentioned normal temperature volatile pyrethroid type insect repellent component.

  As a method of molding this resin composition, any method such as extrusion molding and injection molding can be adopted. When using resin filaments, resin filaments are obtained by extrusion molding or injection molding, and then resin filaments are obtained directly by a method of forming a three-dimensional mesh, or by injection molding the resin composition. The method etc. which form the three-dimensional mesh which it has can be mentioned.

  In the drug volatilization body of the type in which the above-mentioned normal temperature volatilizable drug is kneaded, fine powder components and other resins may be kneaded, if necessary, in addition to the above-mentioned components.

[Fine powder component]
The fine powder component is a component to be added to carry a room temperature volatile agent in a resin pellet. For example, microcrystalline silica, so-called white carbon, finely powdered silicic acid, diatomaceous earth, zeolites, viscosity minerals, wood flour and the like can be mentioned.

  The fine powder component preferably has a number average particle diameter of 1 μm to 30 μm, and more preferably 5 μm to 20 μm. If the number average particle size exceeds 30 μm, the surface area is insufficient even if the content is in the above range, so it becomes difficult to support the insect repellent component as a carrier, and the resulting resin pellet becomes easily sticky. On the other hand, fine particles less than 1 μm are practically difficult and are not preferable because the physical properties are greatly changed.

  The fine powder component containing microcrystalline silica or the like such as white carbon does not react with the insect repellent component, and a fine powder having a large surface area can be used. These fine powder components support the insect repellent component to suppress stickiness, and as a result, the resin composition obtained by kneading together with the resin component is also less sticky as a whole and can be suitably used as a master batch.

[Other resin]
Furthermore, in order to adjust the weight and physical properties of the resin composition, other resins may be kneaded in addition to the constituent resins such as the ethylene-vinyl acetate copolymer. You may contain polyolefin resin and a styrene resin as another resin. Examples of the polyolefin resin include polyethylene (PE) and polypropylene (PP), but polyethylene is preferable in view of affinity with ethylene-vinyl acetate copolymer and ethylene-methyl methacrylate copolymer. Particularly preferred are low density polyethylenes, specifically branched low density polyethylene (LDPE) and linear low density polyethylene (LLDPE).

[Blending ratio]
The compounding amount of the other resin is preferably 10% by mass or more, and more preferably 20% by mass or more, based on the entire resin composition. If it is less than 10% by mass, the effect of suppressing excessive bleeding will be insufficient. On the other hand, the upper limit is preferably 90% by mass or less, and more preferably 60% by mass or less. When the amount is too large, the resin molded product obtained by using the pellets of the resin composition as a master batch and kneading with the other resin excessively suppresses the bleeding too much, and the original purpose of the normal temperature volatile chemical is It is because there exists a possibility that the repellent effect by volatilization may be reduced excessively.

  The content of the fine powder component is preferably 10% by mass or more and 30% by mass or less, and more preferably 15% by mass or more and 25% by mass or less with respect to the entire resin composition. If the amount is less than 10% by mass, the amount of the fine powder component is too small to carry the insect repellent component, which may result in excessive bleeding of the insect repellent component. On the other hand, if it exceeds 30% by mass, it is difficult to maintain the shape of the pellet when the resin composition is pelletized because of the compounding ratio with the constituent resin. Moreover, since it will be contained also in the molded article using the said resin composition, the danger which affects the physical property of a chemical volatilization body is not avoidable when too large.

[Production of Resin Composition and Pellet]
The above resin composition is obtained by heating the above-mentioned constituent resin, and kneading the above-mentioned normal temperature volatilizable agent, and, if necessary, a fine powder component and other heated resin. And by pelletizing this and cooling it, a room temperature volatile drug containing resin pellet can be obtained.

  The heating temperature is usually about 100 ° C. to 140 ° C., although it depends on the type of resin of the constituent resin to be used and the type of resin of other resins. For example, the melting point of an ethylene-vinyl acetate copolymer (manufactured by Tosoh Corp .: Ultracene 710) described later is 70 ° C., and sufficient kneading is possible. If the heating temperature is increased too high to exceed 140 ° C., the thermal decomposition and transpiration loss of the normal temperature volatile drug may be caused, which is not preferable.

  Based on the above, as a typical composition of the resin composition, 10% by mass to 60% by mass normal temperature volatile drug, 10% by mass to 30% by mass fine powder component, and 10% by mass to 60% by mass % Or less of the component resins such as ethylene-vinyl acetate copolymer and the like.

[Mixing time of other resins]
By the way, as described above, the above-mentioned other resin may be contained in the production stage of the above-mentioned normal temperature volatile drug-containing pellet, and the above normal temperature volatile drug-containing pellet is molded without containing this other resin Then, the above-mentioned normal temperature volatile drug-containing pellet may be diluted with the other resin, and then kneaded and molded to obtain the above-mentioned drug volatilization body.

  The dilution factor at this time is preferably 1.5 times or more and the upper limit is about 5 times. If it is less than 1.5 times, there is no merit in the dilution process, while if it is more than 5 times, there is a problem that the content of the insect repellent component must be naturally reduced.

[Manufacturing of drug volatiles]
The normal temperature volatile drug-containing resin pellet can be molded to obtain a drug volatile body. When the other resin is not contained in the normal temperature volatile drug-containing resin pellet, the normal temperature volatile drug-containing resin pellet is diluted with the other resin, and is kneaded and molded as a drug volatile body. It is also good.

[Content of room temperature volatile chemicals]
The content of the normal temperature volatile drug carried on the drug volatile substance is not particularly limited because it varies depending on the type of insect repellent component to be used, the usage environment, the usage condition and the like.
However, in order to secure the amount of the insect repellent component necessary for the insect repellent effect and to facilitate molding after kneading the insect repellent component, it is further prevented that the insect repellent component is excessively bled on the surface of the constituent resin to cause stickiness. In order to achieve this, the content is preferably in the range of 0.5 to 20% by mass.

  When the content of the normal temperature volatile drug is less than 0.5% by mass, it becomes difficult to secure the amount of the insect repellent component necessary for exerting the insect repellent effect, while the content of the normal temperature volatile drug is 20 If the content is more than% by mass, molding after kneading the insect repellent component becomes difficult, and the insect repellent component is excessively bled on the surface of the drug volatile body to cause stickiness.

Here, if the content of the above-mentioned normal temperature volatilizable drug is exemplified, the amount of about 30 to 1400 mg can be raised corresponding to the use period of about 30 to 200 days.
That is, when setting the content, although it varies depending on the type of insect repellent component to be used, for example, when metfluthrin alone is used, the minimum volatilization amount required for the insect repellent effect to appear is 0.03 mg / hr or more Since profluthrin alone is 0.03 mg / hr or more and transfluthrin alone is 0.06 mg / hr or more, the content in 30 to 200 days is 30 to 700 mg for metfluthrin and 30 for It may be set in the range of ̃700 mg, and 60 ̃1400 mg for transfluthrin.

[Mesh structure]
Next, among the drug volatilizers, a structure having a mesh structure will be specifically described.
This mesh structure is a structure having a void having a flat or three-dimensional mesh formed by combining resin rod-like bodies, resin filaments, resin filaments and short fibers (staples) into a fibrous form, etc. It is a body. Among them, a three-dimensional structure having a shape configured into a three-dimensional mesh (hereinafter, referred to as “mesh structure”) can increase the specific surface area of the drug volatilization body, and the drug volatilization amount can be increased. It is preferable because it can be high and long. As a method of forming this mesh structure, first, the above-mentioned normal temperature volatile drug-containing resin pellet is formed by extrusion molding, injection molding or the like to obtain resin rods, resin filaments, short fibers, etc. The fibers are twisted as required into fibers, and then they are used to form a mesh structure, or the above-mentioned normal temperature volatile drug-containing resin pellets are injected directly into a plurality of resin rods by injection molding or the like. It is possible to obtain a mesh structure in which body and resin filaments are crossed.

  As an example of this mesh structure, the three-dimensional structure 1 as shown to Fig.1 (a)-(c) can be mention | raise | lifted. In addition, as a shape of the drug volatilization body which has said mesh structure, it is not limited to these examples.

  The three-dimensional structure 1 shown in FIGS. 1 (a) to 1 (b) has a rectangular wave-like body 11 formed of a resin rod or a resin filament shown in FIG. 1 (c). And at the second top portion 11b), the two corrugated members 11 intersect at substantially right angles. Further, in the three-dimensional structure 1, at least two crests included in one crest-containing surface may be reinforced by a reinforcing material 12 formed of a linear rod-like body. The top portion-containing surface is a surface that constitutes the three-dimensional structure, and is a surface on which the top portion is disposed.

Such a three-dimensional structure 1 can increase the surface area of the resin rod or resin filament present in a certain volume. Furthermore, when the reinforcing material 12 is used, the surface area of the resin filament can be further increased, and the strength of the three-dimensional structure can also be improved.
In addition, a peripheral part is suitably determined by relationship with the intensity | strength of a three-dimensional structure, a shape, an external storage container, etc. FIG.

  When the pellet used for this molding contains a room-temperature volatile drug, this three-dimensional structure 1 becomes the drug volatile body 1a as it is.

[Void ratio]
The content of the space portion in the three-dimensional structure 1 with respect to the porosity of the three-dimensional structure 1, that is, the apparent internal volume of the three-dimensional structure 1 is preferably 70% or more. If it is less than 70%, the flow of air inside the mesh may be interrupted more than necessary, which may lead to the problem that the volatilization and diffusion of the drug on the mesh surface may be reduced. On the other hand, the upper limit of the porosity is preferably 99%. If the amount is more than 99%, the strength for maintaining the three-dimensional mesh structure may be insufficient.

[Cross-sectional shape of resin filament]
An object of the present invention is to optimize the bleeding property of a resin composition that constitutes a carrier and to realize a shape that a normal temperature volatile drug is less susceptible to light when used outdoors. In order to achieve these objects, the resin rod or resin filament is cut into a cross section, and the longest diameter of the diameters passing through the center of gravity is the longest diameter (a) and the shortest diameter is the shortest diameter (b). When it comes to a relationship of a> = b, in addition to this, it is preferred that the shortest diameter (b) fulfills the following conditions. The term "diameter" refers to the length of the figure.

Specifically, the shortest diameter (b) is preferably 0.3 mm or more. If it is less than 0.3 mm, the shape is close to a film, and it can not be avoided that the decomposition of the insect repellent component occurs due to an excessively fast state of the bleed and the influence of light. On the other hand, the upper limit of the shortest diameter (b) is preferably 3.0 mm. If it exceeds 3 mm, the tendency to suppress bleeding is intensified, and the size (porosity) of the mesh (opening) of the resin mesh to be described later may be narrowed to cause a decrease in the volatilization efficiency.
In addition, the longest diameter (a) is preferably 0.3 mm or more. If it is less than 0.3 mm, the shape is close to a film, and it can not be avoided that the decomposition of the insect repellent component occurs due to an excessively fast state of the bleed and the influence of light. On the other hand, the upper limit of the longest diameter (a) is preferably 10 mm. If it exceeds 10 mm, the tendency to suppress bleeding is intensified, and the size (porosity) of the mesh (opening) of the resin mesh to be described later is narrowed, which may cause a decrease in the volatilization efficiency.

  As a cross-sectional shape of the said resin rod-shaped body or resin filament which satisfy | fills the above conditions, the oval shape shown to Fig.2 (a), the square shape shown to FIG.2 (b), the rhombus shown to FIG.2 (c) Although not shown in the drawings, examples include polygonal shapes such as rectangular shapes and trapezoidal shapes although not shown, but are not limited thereto. In addition, in Fig.2 (a)-(c), a shows a longest diameter and b shows a shortest diameter.

  Also, the size (porosity) of the mesh (openness) of the mesh is not particularly limited as long as the porosity is satisfied, but it is considered from the point of volatilization efficiency and air permeability, and under the conditions satisfying the porosity Preferably, it is in the range of 40 to 85%, and more preferably 50 to 75%.

  Further, the shape of the mesh of the mesh is not limited to the triangular shape shown in FIGS. 1 (a) to 1 (b), and may be appropriately set to a square, a diamond, a hexagon, etc. as necessary.

[Container]
In the present invention, the drug volatilization body 1a is used by being stored in the storage container 32, as shown in FIG. The drug volatilization body 1 a is swingably suspended inside the storage container 32. In this suspension, the drug volatilization body 1a may be suspended at least at one point inside the storage container 32, and as shown in FIG. 4A, it is suspended at one point via the suspension member 31. Preferably it is lowered.

  The shape, the size, and the length of the suspending member 31 are not particularly limited as long as the suspending agent 31 can suspend the drug volatilizing body firmly and can volatilize the room temperature volatilizing drug stably. Moreover, as a material of the suspending member 31, materials such as paper, yarn (twist yarn etc.), non-woven fabric, wood, pulp, chemical fiber, polyester, polyethylene, polystyrene, polyethylene terephthalate and other resin materials can be used.

  The shape and size of the storage container 32 are not particularly limited, as long as the container can stably volatilize the normal temperature volatile chemical, and the length for suspending the drug volatile substance 1a inside the storage container 32 is also not limited. It is not limited.

The storage container 32 has an opening, and the opening is provided at least on the side surface or front surface of the storage container 32. On the other hand, almost no opening is provided on the back surface, and even if provided, a small amount is sufficient. In the case where the drug volatilization apparatus according to the present invention is used as a portable type on the back side, the venting component of the room temperature volatilizable drug is delivered to the body side and hardly comes into contact with the body by hardly providing the opening. It can be reduced and is preferred.
Note that openings may be provided in the upper and lower surface portions of the storage container 32 as necessary.

  The ratio (aperture ratio) of the area (C) of the opening provided in the side surface of the storage container 32 to the total area of the side surface of the storage container 32 is in the range of 10 to 50% from the point of volatilization efficiency. It is preferable that

  The ratio (aperture ratio) of the area (D) of the opening provided in the front of the storage container 32 to the total area of the front of the storage container 32 is 10 to 50% from the point of volatilization efficiency. It is preferable to make it a range.

  Furthermore, the ratio (C / D) of the area (C) of the opening provided in the side face of the storage container 32 to the area (D) of the opening provided in the front face is the point of volatilization efficiency and air permeability. Preferably, it is in the range of 0.3 to 3.0.

  By the way, the ratio (aperture ratio) of the area of the opening provided in the back surface of the storage container 32 to the total area of the back surface of the storage container 32 is the case where the chemical vaporization apparatus according to the present invention is used as a portable type In order to prevent the volatilization component of the normal temperature volatile drug from coming into contact with the body side as much as possible, it is preferably 10% or less, preferably 0%, that is, the case where the opening is not provided.

  In addition, if the area of an opening part is the said range, the shape of the said opening part is not restricted to the shape shown to Fig.3 (a), It does not specifically limit.

The shape of the storage container is not particularly limited as long as a swing angle described later can be secured, and a hexagonal column as shown in FIGS. 5 (b) and 5 (c) other than the shape of the square pole shown in FIG. The shape of a polygonal prism such as the shape of a pentagonal prism, the shape of a side of a cylinder such as a cylindrical shape as shown in FIG. 5 (d) is a curved surface, the shape of a curved surface or a flat is not shown. can give.
Moreover, according to the shape (for example, flat plate shape, cylindrical shape, etc.) of a chemical volatilization body, the above-mentioned various shapes are employable in the range which can secure the rocking angle mentioned below.
Furthermore, in the case of being applied to mounting an air purifier, it is sufficient that the chemical volatilization body can be swingably suspended even if the storage container is simplified as appropriate.

  By the way, in the above-mentioned aperture ratio, the term "front part", "side part", and "back part" were used. In the quadrangular prism shape in FIG. 5 (a), when the smallest surface of the opening (the aperture ratio is 10% or less) is the back surface (indicated as “B” in FIG. 5), the opposite surface of the back surface is Because the front part (F) is formed and the side part (S) is formed between the front part and the back part, the determination is not difficult. However, in the case of FIG. 5 (b)-(d), it may be difficult to judge. Therefore, in the present invention, the "front portion", the "side portion", and the "back portion" are classified according to the following criteria.

First, in the case of a polygonal prism shape as shown in FIGS. 5A to 5C, the surface with the smallest number of openings (aperture ratio of 10% or less) is taken as the “rear surface” (B).
Also, if there is a surface facing the back surface and a surface parallel to the back surface, that surface is referred to as "front surface" (F).
Furthermore, when the angle between the surface constituting the back surface portion and the surface is 45 ° or less, the surface is referred to as “front portion” (F), and the other surfaces are referred to as “side surface” (S).

Next, in the case of a cylindrical shape as shown in FIG. 5D, consider division by a straight line parallel to the axial direction (hereinafter sometimes referred to as “division line”). First, the side circumferential surface is divided by two dividing lines, and a section having an aperture ratio of 10% or less and a half or less of the circumferential direction of the side circumferential surface is referred to as “rear surface portion” (B). When the section where the aperture ratio is 10% or less exceeds half of the circumferential direction of the side circumferential surface, the circumferential half of the side circumferential surface where the aperture ratio is the smallest is the “rear surface” (B) I assume.
In addition, the portion other than the back surface portion is first divided into four equal parts by dividing lines. Next, in the vicinity of this dividing line, a dividing line passing through the center of the portion where the gap between the openings is the largest is taken as a boundary line. Of the four fractions separated by this boundary line, the two fractions at both ends are referred to as the "side part" (S), and the remaining two fractions of the central part are referred to as the "front part" (F) .

  Examples of the structure of the storage container include one obtained by bending a flat sheet-like plastic member, an integrally molded product of plastic, and the like.

  In the case where the flat sheet-like plastic member is folded, the storage container is assembled such that two folded members are used as a set and the folding surfaces of the respective members overlap.

  Various plastic materials such as polyethylene terephthalate, polyethylene, polypropylene, polybutylene terephthalate, nylon, polyamide, etc. can be used as the plastic material used for these flat sheet-like plastic members and integrally molded products of plastic. In view of its properties, it is preferable to use polyethylene terephthalate (PET) or polybutylene terephthalate (PBT).

  In addition, although various types of these plastics can be used, it is preferable to use one having a thickness of 0.05 to 2 mm from the viewpoint of the shape of the constituent resin, the relationship with its volatilization performance, and economic efficiency. preferable.

  By the way, it is possible to provide a cut tongue portion at the end of the bent surface of the bent member and extend the hook portion so as to be able to turn it up (not shown). In this case, a storage window for folding the hook portion may be provided above the rear surface portion. This makes it possible to use in accordance with various usage methods, for example, for portable use, for hanging and the like.

  That is, when the tip end portion of the hook portion is locked to, for example, the upper surface portion of the storage container, in the case of use for a waist belt or the like of the body, the storage container is accidentally dropped by body movement There is no problem and you can expect a certain effect at the part you want to use.

  Next, although the molding method does not matter as long as the plastic integrally molded product is a molded product by ordinary injection molding or vacuum molding, etc., the upper surface part and the lower surface part and the front surface part and the back surface part use hinges. By integrating them together or fitting them together, the manufacturing process can be further simplified.

  Further, in this case, if hooks are provided on the upper surface of the storage container so as to be able to be raised, they can be securely attached to the body similarly to the above, and can be used for portable use. That is, in the same manner as described above, when the distal end portion of the hook portion is configured to be able to be locked to a part of the storage container, for example, an opening or a recess provided on the upper surface at the time of use, In the case of use, there is no problem such as accidental drop, and a reliable effect can be expected in the place where it is desired to use.

  Moreover, although it is an item suitably selected at the time of manufacture as to which part of a storage container the above-mentioned hook part is locked, if it locks on the same surface as the surface in which the hook part is provided, use Since it can prevent that a storage container moves from an installation position at the time, it is preferable.

[Drug stripping device]
As described above, the chemical volatilization device 30 is formed by swingably suspending the chemical volatilization body 1a in the storage container 32, as shown in FIGS. 3 and 4A. The drug volatilization body 1a swings due to an external factor such as a wind entering the inside of the storage case 32 from the outside, movement of the storage case 32, and the like. By this fluctuation, volatilization of the volatilizable drug contained in the drug volatilization body 1a is caused or the volatilization amount thereof is increased. Then, the volatilized volatilizable drug (hereinafter sometimes referred to as "gaseous drug") remains in the void portion of the drug volatilization body. The retained gaseous drug is moved to and retained in the space in the storage container 32 by the new gaseous drug produced by the swing of the drug volatilization body 1a. When generation of a new gaseous drug continues due to the swing of the drug volatilization body 1a, the gaseous drug retained in the space in the storage container 32 is related to the ratio of the opening of the storage container 32, When the concentration reaches a certain level, it is delivered to the outside of the storage container 32.
In this case, since the gaseous drug which comes out of the storage container 32 is kept at a predetermined speed and exits, the medicinal effect of the volatile chemical, for example, the effect such as insecticidal and insect repellent can be exhibited.

  The ratio of the space in the storage container 32 is the bulk volume (A) of the drug volatilization body 1a, that is, the volume including the void portion of the drug volatilization body 1a and the volume (B) inside the storage container 32. When it shows with ratio (A / B), 0.01 or more is good and 0.1 or more is preferable. If it is less than 0.01, it may be out of the storage container 32 while the concentration of the gaseous drug staying in the space in the storage container 32 is not sufficient. On the other hand, the upper limit of the volume ratio (A / B) is preferably 0.6, preferably 0.4. When it is larger than 0.6, it becomes difficult for the drug volatilization body to swing, and the volatilization amount of the drug is suppressed.

By the way, in order to produce the above-mentioned gaseous medicine, it is necessary to rock the medicine volatilization body 1a within the storage container 32. The direction of this swing is the swing in the lateral direction (direction between one side portion and the other side portion) of the drug volatilization body 1a as shown in FIG. 3 (b), or FIG. 3 (c) The present invention is not limited to swinging in the front-rear direction (direction between the front and back portions) of the drug volatile body 1a as shown, but includes swinging in any direction. Then, among the above, the "swing angle" may simply be displayed for the maximum swing angle.
In addition, the angle (swing angle) of this swing may be shown by "(theta)" henceforth. In addition, (theta) shown in FIG.3 (b) (c) means the rocking angle of a horizontal direction or the front-back direction.

  The state of the drug volatilization body 1a colliding with the storage container 32 is the limit of the range of the rocking. The maximum swing angle (θ) is preferably 0.05π (that is, 9 °) or more, and preferably 0.1π (18 °). If the ratio is less than 0.05π, the ratio of the space in the storage container 32 is too small, and therefore, it leaves the storage container 32 while the concentration of the gaseous drug remaining in the space in the storage container 32 is not sufficient. There are times when The upper limit of the maximum rocking angle (θ) is preferably 0.5π (90 °), and more preferably 0.2π (36 °). Is preferred. If it is larger than 0.5π, the proportion of the space in the storage container 32 is too large, so the medicine volatilization apparatus 30 itself becomes large, and it may be inconvenient to carry when it is portable.

[Storage bag]
The drug volatilization body of the present invention is generally stored in a storage container, stored in a drug impermeable film bag, marketed, and opened for use. Of course, only the drug volatilization body may be contained in a drug impermeable film bag and marketed, and the drug volatilization body removed from the bag at the time of use may be loaded into the storage container. Here, as the material of the drug impermeable film bag, polyester (PET, PBT, etc.), polyamide, polyacetal, polyacrylonitrile, etc. may be mentioned, and the thickness thereof is determined within a range that does not impair the flexibility. In addition, in order to provide heat sealability, the inner surface of these drug non-permeable films can also be laminated with polyethylene, a polypropylene film, or the like.

[Use]
The drug volatilization apparatus 30 prepared according to the present invention can be mosquitoes such as Culex pipiens, Culex pipiens, Helicoverpa armigera, Bulimia nervosa, for a predetermined period according to its design specifications for at least 60 days or longer and up to approximately 200 days immediately after use. It exerts an excellent insect repellent effect on species, flies, butterflies and moths.

  The drug volatilization device 30 is a portable type as shown in FIG. 6, and is worn on a body part such as a waist belt or attached with a string and hung from a neck, whereby the drug volatilization device 30 The movement of the medicine volatilization body 1a is caused to move, and it becomes possible to use it for insect control when taking a walk or the like.

  If the hook is hooked to a curtain rail or hung on a clothesline at a window or veranda that separates the room from the room, for example, the drug volatilization device 30 is moved by wind or the like, causing the drug volatilization It is possible to cause the swing of 1a and effectively prevent the infestation of these pests from the outside to the inside, which is extremely practical.

  Furthermore, as shown in FIG. 6, the chemical volatilization apparatus 30 can be used by attaching it to a pet dog's lead, or the storage container can be appropriately simplified and used for attachment of an air cleaner or the like.

[Characteristics of drug volatilization body]
The drug volatilization body of the present invention can be stably manufactured in quality by having the above-mentioned configuration.

Next, the chemical volatilization apparatus of the present invention will be described using an example. The embodiments described below are merely examples embodying the present invention, and do not limit the technical scope of the present invention.
First, the agents used and the method of evaluating the performance will be described.

<Raw materials>
・ Metofluthrin (Sumitomo Chemical Co., Ltd. product: Eminence)
・ Transfluthrin (Sumitomo Chemical Co., Ltd. product: Biothrin)
Microcrystalline silica (manufactured by EVONIK: Carplex # 80, white carbon, average particle size: 15 μm, hereinafter referred to as "silica")
Ethylene-vinyl acetate copolymer (manufactured by Tosoh Corp .: Ultracene 710, ethylene: vinyl acetate unit ratio = 72: 28, hereinafter referred to as “EVA”)
Low density polyethylene (manufactured by Asahi Kasei Co., Ltd .: Suntec LDM 6520, hereinafter referred to as "LDPE-A")
Polyethylene terephthalate (manufactured by Bell Polyester Products Co., Ltd .: Bellpet IP121B, hereinafter referred to as "PET")

<Examination evaluation test of volatile chemicals>
The obtained drug volatilization body is separated by a 5 mm suspension member from the upper center of the inside of the storage container having the opening shown in Table 2 and having the opening shown in Table 2 and the opening shown in Table 2 Suspended, placed on a shaker in a room at 25 ° C, shaken for 1 hour for 10 minutes, and contained in a three-dimensional structure mesh for a predetermined period (the middle point of the effective period, the end point) after volatilization starts The amount of active ingredient was respectively measured by gas chromatography, and the amount of chemical volatilization per day was calculated.

<Overall evaluation>
The following criteria were evaluated from the chemical volatilization amount of the volatile chemical, the effective volatilization amount of the chemical to be used, and the effective period. The term "effective volatilization amount" means an amount that the drug works effectively against pests, and is 0.03 mg / h or more for metfluthrin and 0.06 mg / h or more for transfluthrin. The term "effective period" refers to a standard of a period for effectively controlling pests, which is set in view of the content of the drug contained in the drug volatilizer and the product of the applicant of the past.
◎: The amount of chemical volatilization at the end of the effective period was kept higher than the effective volatilization amount.
○: The amount of chemical volatilization at the end of the effective period was kept higher than the amount of effective volatilization, but a slightly lower tendency was observed compared to “◎”.
Δ: The amount of chemical volatilization at the end of the effective period is the lower limit value of the effective volatilization amount.
X: The amount of chemical volatilization at the end of the effective period is lower than the effective volatilization amount.

<Manufacturing of drug volatiles>
(Production Example 1)
(Production of Metofluthrin-containing Drug Volatilizer)
After 10 parts by weight of metfluthrin warmed to 50 ° C. was supported on 6 parts by weight of microcrystalline silica, 40 parts by weight of EVA and 44 parts by weight of LDPE-A were used, manufactured by Technobel Co., Ltd .: using a twin screw extruder The mixture was kneaded and extruded at 120 to 140 ° C. to produce metfluthrin-containing resin pellets having a diameter of 3 mm and a length of 5 mm.

After kneading 100 parts by weight of the above metfluthrin-containing resin pellets and 300 parts by weight of LDPE-A (including 10 parts by weight of colorant pellets) at 120 to 140 ° C., the mixture is charged into an injection molding machine and a mesh consisting of the three-dimensional structure shown in FIG. Powdery volatile substance (10 g) was obtained.
As shown in Table 1, the cross-sectional shapes of the resin filaments of the rectangular corrugated body 11 and the reinforcing material 12 constituting this three-dimensional structure are squares of 1.3 mm × 1.3 mm, and the shortest diameter (b) is 1.0 mm, The ratio of the longest diameter (a) to the shortest diameter (b) was 1.4. The size of the entire drug volatilization body was 50 mm × 50 mm × 50 mm. And the porosity was 97%. Hereinafter, the obtained drug volatilization body is referred to as "MA".

(Production Examples 2 to 5)
Using the amounts of drug used in Table 1, drug volatilizers were produced with the size of each of the meshes described in Table 1. The porosity is as shown in Table 1. The resulting drug volatilizers are hereinafter referred to as "MB", "MC", "TA" and "TB", respectively.

(Examples 1 to 13, Comparative Examples 1 to 11)
The obtained drug volatilization body was housed in a container shown in Table 2, and the volatilization amount and the volatilization time of the volatilizable drug were measured based on the method described in the above-mentioned <Evaluation Test of Volatilization Property of Volatile Drug>. The results are shown in Table 2.

(result)
As a result of the test, in the case of the non-oscillation (the oscillation angle is less than 0.05π), the amount of drug volatilization at the end point in particular has not reached the effective volatilization amount, and has a sufficient amount of drug volatilization It became clear that it did not (comparative examples 1-11).
On the other hand, those capable of swinging were able to obtain volatilization amounts higher than those without swinging (a swing angle is less than 0.05π), and maintained high effective volatilization amounts up to the end point (Examples 1 to 4) 13).
In addition, when the open area ratio (C and D) is 10 to 50% and the C / D is in the range of 0.3 to 3.0, the effective volatilization amount of the volatile drug is maintained high even at the end of the evaluation (Examples 2, 3, 7, 10, 11, 12).
On the other hand, when C / D is not in the range of 0.3 to 3.0, the amount of drug volatilization at the end is lower than in the case where this range is satisfied, and the maintenance of the amount of drug volatilization is slightly insufficient It can be seen (Examples 4, 9, 13).
In addition, when the opening ratio (C and D) exceeds 50%, the amount of volatilization increases, the amount of drug volatilization at the end is low, and maintenance of the amount of drug volatilization is slightly insufficient compared to the case where this range is satisfied. The face can be seen (Examples 1 and 5).
Furthermore, it was found that when the rear opening ratio was 10% or less, there was not much difference in the results (Examples 5 and 6).
On the other hand, when the rear opening ratio exceeds 10%, the amount of volatilization increases, and the amount of drug volatilization at the end is low compared to the case where this range is satisfied, and it can be seen that the maintenance of the amount of drug volatilization is slightly insufficient Example 8).

(Example 14)
A plain textured fabric was knitted on both sides using a PET processed yarn as a fiber component consisting of a resin, and the both sides were connected with a filament twisted to prepare a three-dimensional knitted fabric with a thickness of 3 mm. The shortest diameter of the cross section of the filament constituting this three-dimensional structure was 0.3 mm, and the size of the entire three-dimensional structure was 150 mm × 80 mm. In addition, the porosity was 81%.
A drug solution in which 0.25 g of metfluthrin was dissolved in 0.25 g of acetone was retained in the steric structure. When the volatilization amount and volatilization time of the volatilization drug were measured based on the above method using the obtained drug volatilization body, the average volatilization amount was 0.03 mg / hr and the volatilization time was 60 days.

  The present invention can be used for a long time in the field of pest control using a drug volatilization body.

DESCRIPTION OF SYMBOLS 1 three-dimensional structure 1a drug volatilization body 11 rectangular corrugated body 11a 1st top part 11b 2nd top part 12 reinforcement material 30 drug volatilization apparatus 31 suspension member 32 storage container a longest diameter b shortest diameter

Claims (5)

It is a medicine volatilization apparatus which stored the medicine volatilization body which made the carrier carry a normal temperature volatilizable drug on the inside of a storage container having an opening.
Providing the opening at least on the side and front of the container;
The ratio (C) of the area of the opening of the side part to the area of the whole side part of the storage container is 10 to 50%,
The ratio (D) of the area of the opening of the front part to the area of the entire front part of the storage container is 10 to 50%,
This area ratio C / D is 0.3 to 3.0,
The area of the opening provided in the back of the storage container is 10% or less of the total area of the back of the storage container,
The drug volatilization body is suspended at one point inside the storage container,
The chemical volatilization body, pivotable in any direction including directions between the direction between the one side surface portion and the other side portion of the container, and a rear portion and the front portion of the receiving container Yes ,
The maximum swing angle of the drug volatilization body is 0.05π (9 °) to 0.2π (36 °) ,
The volume ratio (A / B) of the bulk volume (A) of the drug volatilization body to the volume (B) inside the storage container is 0.01 to 0.6,
By swinging the drug volatilization body, volatilization of the volatilization drug contained in the drug volatilization body is caused, or the volatilization amount thereof is increased.
The chemical volatilization apparatus which makes the gaseous chemical | medical agent which is this volatilization volatilization drug move to the space part in the said storage container from the cavity of a drug volatilization body, and sends it out from the said opening part. The drug volatilization device according to claim 1 , wherein the drug uses at least one drug selected from transfluthrin, metfluthrin, enpentrin and profluthrin. The drug volatilization device according to claim 1 or 2 , wherein the carrier is a flat plate-like or three-dimensional structure composed of a fiber component or a resin component. The drug stripping apparatus according to claim 3 , wherein the carrier has a mesh structure having a void. The medicine volatilization apparatus according to any one of claims 1 to 4 , which is portable.

Images